# Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery

> **NCT04877756** · PHASE2 · COMPLETED · sponsor: **Olix Pharmaceuticals, Inc.** · enrollment: 22 (actual)

## Conditions studied

- Hypertrophic Scar

## Interventions

- **DRUG:** OLX10010

## Key facts

- **NCT ID:** NCT04877756
- **Lead sponsor:** Olix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-19
- **Primary completion:** 2023-01-11
- **Final completion:** 2023-07-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04877756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04877756, "Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04877756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*